AD Glymphatic System and CSF Dynamics Therapy Companies

📖 Wiki Page

company1019 wordssynced 2026-04-02

Overview

flowchart TD companies_ad_glymphatic_csf_th["AD Glymphatic System and CSF Dynamics Therapy Co"] style companies_ad_glymphatic_csf_th fill:#4fc3f7,stroke:#333,color:#000 companies_ad_glympha_0["Key Companies"] companies_ad_glymphatic_csf_th -->|"includes"| companies_ad_glympha_0 style companies_ad_glympha_0 fill:#81c784,stroke:#333,color:#000 companies_ad_glympha_1["Cyclia Therapeutics"] companies_ad_glymphatic_csf_th -->|"includes"| companies_ad_glympha_1 style companies_ad_glympha_1 fill:#ef5350,stroke:#333,color:#000 companies_ad_glympha_2["Vera Therapeutics"] companies_ad_glymphatic_csf_th -->|"includes"| companies_ad_glympha_2 style companies_ad_glympha_2 fill:#ffd54f,stroke:#333,color:#000 companies_ad_glympha_3["Alnylam Pharmaceuticals"] companies_ad_glymphatic_csf_th -->|"includes"| companies_ad_glympha_3 style companies_ad_glympha_3 fill:#ce93d8,stroke:#333,color:#000 companies_ad_glympha_4["Cyclocera formerly Accera"] companies_ad_glymphatic_csf_th -->|"includes"| companies_ad_glympha_4 style companies_ad_glympha_4 fill:#4fc3f7,stroke:#333,color:#000 companies_ad_glympha_5["Cereve Mitochondrial Protection"] companies_ad_glymphatic_csf_th -->|"includes"| companies_ad_glympha_5 style companies_ad_glympha_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

The glymphatic system is a macroscopic waste clearance pathway in the brain that utilizes perivascular tunnels formed by astroglial AQP4 water channels to clear soluble amyloid-beta (Abeta), tau proteins, and other metabolic waste products during sleep. Cerebrospinal fluid (CSF) dynamics — including CSF production, circulation, and drainage — are integral to this brain clearance system.

In Alzheimer's disease, glymphatic clearance becomes significantly impaired, contributing to accumulation of toxic protein aggregates. This category page catalogs companies developing therapies targeting:

Glymphatic system enhancement
Brain waste clearance optimization
CSF production and flow enhancement
Perivascular pumping mechanisms
Meningeal lymphatic function
AQP4 water channel modulation

Key Companies

Cyclia Therapeutics

Cyclia Therapeutics is developing therapies targeting the glymphatic system for neurodegenerative disease:

| Attribute | Details |
|-----------|---------|
| Focus | Glymphatic system enhancement |
| Platform | Perivascular clearance modulation |
| Indication | Alzheimer's disease, Parkinson's disease |
| Stage | Preclinical |
| Mechanism | AQP4 polarization enhancement |

Scientific Rationale: The glymphatic system relies on AQP4 water channels in astrocyte end-feet surrounding cerebral blood vessels. Cyclia is developing small molecules and biologics to enhance AQP4 polarization and perivascular flow, potentially improving clearance of Aβ and tau from the brain parenchyma.

Vera Therapeutics

Vera Therapeutics is focused on CSF dynamics and brain waste clearance:

| Attribute | Details |
|-----------|---------|
| Focus | CSF production and flow |
| Platform | CSF dynamics modulation |
| Indication | Alzheimer's disease, Normal Pressure Hydrocephalus |
| Stage | Preclinical |

Innovation: Vera is targeting CSF production via the choroid plexus and improving CSF circulation through the ventricular system and subarachnoid space. Enhanced CSF flow may improve clearance of solutes from the brain interstitium via the glymphatic pathway.

Alnylam Pharmaceuticals

Alnylam is pioneering RNA interference (RNAi) therapeutics with a focus on brain delivery through transferrin receptor (TfR)-targeting:

| Attribute | Details |
|-----------|---------|
| Focus | siRNA delivery to brain via TfR |
| Platform | GALNAC-conjugated siRNA with TfR targeting |
| Indication | CNS diseases including AD |
| Stage | Preclinical |

Innovation: Alnylam's TfR-targeted approach enables siRNA delivery across the BBB. The company has explored reducing production of amyloid precursor protein (APP) in the brain as a potential disease-modifying approach. Additionally, siRNA targeting AQP4 may modulate glymphatic function.

Cyclocera (formerly Accera)

Cyclocera developed AC-1204 (Ketasulin), a compound designed to improve cerebral glucose metabolism:

| Attribute | Details |
|-----------|---------|
| Focus | Cerebral glucose metabolism, sleep-dependent clearance |
| Lead Candidate | AC-1204 (Ketasulin) |
| Indication | Alzheimer's disease |
| Stage | Phase 3 (discontinued 2019) |
| Mechanism | Ketogenic agent |

Rationale: Cerebral glucose hypometabolism is a hallmark of AD. Additionally, sleep-dependent glymphatic clearance is enhanced during ketogenesis. By providing an alternative fuel source (beta-hydroxybutyrate), Ketasulin aimed to improve neuronal energy supply and potentially enhance sleep-dependent waste clearance.

Cereve (Mitochondrial Protection)

Cereve (formerly Edison Therapeutics) focused on mitochondrial protection in neurodegenerative disease:

| Attribute | Details |
|-----------|---------|
| Focus | Mitochondrial dysfunction in neurovascular unit |
| Lead Candidate | CVT-31345 |
| Stage | Preclinical |
| Mechanism | Mitochondrial ATP-sensitive potassium channel activators |

Notes: While primarily focused on mitochondrial protection, improved endothelial mitochondrial function supports perivascular pumping and glymphatic clearance. The neurovascular unit's metabolic health is integral to glymphatic system function.

Therapeutic Targets

1. AQP4 Water Channels

AQP4 (Aquaporin-4) is the primary water channel in the glymphatic system:

| Target | Approach | Companies |
|--------|----------|------------|
| AQP4 polarization | Small molecule modulators | Cyclia Therapeutics |
| AQP4 expression | Gene therapy | Research |
| AQP4 trafficking | Kinase inhibitors | Research |

2. Meningeal Lymphatics

Meningeal lymphatic vessels drain waste from the brain to cervical lymph nodes:

| Target | Approach | Companies |
|--------|----------|------------|
| Lymphatic growth | VEGF-C agonists | Research |
| Drainage optimization | Physical modulation | Research |
| Inflammation reduction | Anti-inflammatory | Research |

3. Perivascular Pumping

arterial pulsations drive glymphatic flow:

| Target | Approach | Companies |
|--------|----------|------------|
| Pulse amplitude | Vasomodulators | Research |
| Vessel compliance | Smooth muscle modulators | Research |
| Astrocyte end-feet | AQP4 enhancers | Cyclia |

4. Sleep-Dependent Clearance

Sleep is essential for maximal glymphatic activity:

| Target | Approach | Companies |
|--------|----------|------------|
| Sleep optimization | Orexin antagonists | Multiple |
| Circadian entrainment | Light/melatonin therapy | Multiple |
| Metabolic state | Ketogenic agents | Cyclocera |

5. CSF Dynamics

CSF production and flow are foundational to glymphatic function:

| Target | Approach | Companies |
|--------|----------|------------|
| Choroid plexus function | CSF production modulators | Vera Therapeutics |
| Ventricular flow | Intranasal delivery | Research |
| Subarachnoid circulation | Physical therapy | Research |

Clinical Trial Landscape

| Company | Drug/Approach | Phase | Indication | Status |
|---------|--------------|-------|------------|--------|
| Cyclia Therapeutics | AQP4 modulators | Preclinical | AD | Development |
| Vera Therapeutics | CSF dynamics | Preclinical | AD/NPH | Development |
| Alnylam | siRNA brain delivery | Preclinical | AD | Development |
| Multiple | Orexin antagonists | Phase 2/3 | AD | Active |

Scientific Rationale

Evidence for Glymphatic Dysfunction in AD

AQP4 polarization loss: Reduced perivascular AQP4 in AD brains correlates with impaired clearance

Sleep disruption: Reduced deep sleep compromises 70% of glymphatic clearance

Cerebral small vessel disease: White matter lesions impair perivascular flow

Pericyte loss: Reduced pericyte coverage affects capillary pulsations

Meningeal lymphatic decline: Age-related lymphatic dysfunction reduces drainage

Therapeutic Implications

Sleep enhancement: Optimizing sleep architecture may significantly boost clearance
AQP4 targeting: Direct modulation of water channel function offers direct pathway enhancement
Combination approaches: Glymphatic enhancement combined with amyloid/tau targeting may improve outcomes
Early intervention: Glymphatic dysfunction precedes clinical symptoms — potential for prevention

Cross-Links

[Glymphatic System](/mechanisms/glymphatic-system)
[Glymphatic Clearance and AD](/mechanisms/glymphatic-clearance-ab-tau-hypothesis)
[AD Neurovascular Therapy Companies](/companies/ad-neurovascular-cerebral-vasculature-therapy-companies)
[Sleep and Tau Clearance](/mechanisms/sleep-tau-clearance)
[AQP4 Water Channels](/proteins/aqp4)
[Meningeal Lymphatics](/mechanisms/meningeal-lymphatics)
[Brain Waste Clearance Technologies](/technologies/brain-waste-clearance-therapies)

References

[Cyclia Therapeutics](https://www.cyclicatherapeutics.com)

[Vera Therapeutics](https://www.veratherapeutics.com)

[Alnylam BBB Delivery Platform](https://www.alnylam.com)

[Cyclocera](https://www.cyclocera.com)

AD Glymphatic System and CSF Dynamics Therapy Companies

Overview

Overview

Key Companies

Cyclia Therapeutics

Vera Therapeutics

Alnylam Pharmaceuticals

Cyclocera (formerly Accera)

Cereve (Mitochondrial Protection)

Therapeutic Targets

1. AQP4 Water Channels

2. Meningeal Lymphatics

3. Perivascular Pumping

4. Sleep-Dependent Clearance

5. CSF Dynamics

Clinical Trial Landscape

Scientific Rationale

Evidence for Glymphatic Dysfunction in AD

Therapeutic Implications

Cross-Links

References

See Also